ESR1 and triple-negative breast carcinoma: Studies showed that CXCR4 is involved in resistance to chemotherapies, including paclitaxel, a taxane similar to docetaxel, in ovarian cancer [54] and ER+ or triple-negative breast cancer cell lines [55].